Synriam (Arterolane/Piperaquine)
| Active Ingredient | Arterolane/Piperaquine |
|---|---|
| Indication: | Malaria |
| Manufacturer: | Sun Pharmaceutical Industries Ltd |
| Packaging | 3 Tablets in Strip |
| Strength | 150mg/750mg |
| Delivery Time | 6 To 15 days |
Synriam is a fixed-dose combination antimalarial medication containing Arterolane maleate (150 mg) and Piperaquine phosphate (750 mg), designed for the treatment of uncomplicated malaria, particularly Plasmodium falciparum infections. It is an innovative, once-daily, 3-day oral therapy developed to offer rapid parasite clearance with high efficacy, including against drug-resistant strains.
Arterolane acts quickly to kill malaria parasites during the blood stage, offering fast symptom relief, while Piperaquine has a long half-life that ensures sustained activity, reducing the risk of recurrence. Synriam is the first New Chemical Entity developed and manufactured in India, and it has been included in India’s national malaria control program.








There are no reviews yet.